Serum levels of ILs and RAS components at baseline and post-treatment in placebo and vitD treated groups

Serum levels of ILs and RAS componentsBaseline vs. placebo treatmentBaseline vs. vitD treatmentChange from baseline vitD treated vs. placebo treated
IL-6 (pg/mL)Baseline
Post-treatment		19.9 ± 5.3 vs.
17.6 ± 5.8		27.7 ± 8.8 vs.
35.1 ± 21.0		7.4 ± 22.4 vs.
−2.2 ± 4.1
IL-8 (pg/mL)Baseline
Post-treatment		17.9 ± 5.0 vs.
17.4 ± 4.0		20.9 ± 3.4 vs.
30.8 ± 16.3**		9.8 ± 13.9 vs.
−0.5 ± 6.1
IL-1B (pg/mL)Baseline
Post-treatment		6.3 ± 1.2 vs.
7.5 ± 1.4*		7.2 ± 0.8 vs.
5.5 ± 0.4		−1.7 ± 0.4 vs.
1.2 ± 0.4
TNF-α (pg/mL)Baseline
Post-treatment		12.3 ± 2.4 vs.
12.7 ± 3.7		12.6 ± 1.7 vs.
9.0 ± 3.1		−3.6 ± 3.0 vs.
0.3 ± 3.1
IL-10 (pg/mL)Baseline
Post-treatment		29.2 ± 3.8 vs.
31.4 ± 7.2		35.6 ± 7.1 vs.
63.7 ± 35.9		28.1 ± 35.5 vs.
2.2 ± 6.0
Ang-(1-7) (pg/mL)Baseline
Post-treatment		851.2 ± 130.8 vs.
1014.4 ± 170.3*		645.3 ± 68.5 vs.
977.9 ± 190.1**		332.6 ± 148.2 vs.
163.1 ± 55.7
Ang-II (pg/mL)Baseline
Post-treatment		209.0 ± 43.9 vs.
81.0 ± 21.3**		132.2 ± 24.2 vs.
86.9 ± 27.5**		−45.2 ± 19.5 vs.
−128.0 ± 26.0*
Ang-(1-7)/Ang-2Baseline
Post-treatment		2.5 ± 0.3 vs.
8.6 ± 2.3*		5.2 ± 1.2 vs.
17.7 ± 4.7**		12.5 ± 3.7 vs.
6.0 ± 2.2

Changes from baseline. The results are shown as mean ± standard error mean (SEM). * P < 0.05; ** P < 0.01